Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
76.95 SEK | -0.06% | +4.13% | -6.52% |
09:45am | Elekta to Buy Philips Healthcare's Treatment Planning Patent Portfolio | MT |
Apr. 22 | Elekta, GE HealthCare Team Up for New Cancer Treatment Planning Services | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.52% | 2.7B | A | ||
+8.14% | 218B | B | ||
+7.23% | 183B | B- | ||
+13.13% | 134B | B- | ||
+26.12% | 106B | A- | ||
-1.33% | 61.12B | A- | ||
+4.81% | 50.89B | B+ | ||
+0.17% | 40.3B | A | ||
+2.72% | 35.53B | - | ||
+26.52% | 32.05B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EKTA B Stock
- Ratings Elekta AB